{"id":21611,"date":"2025-02-05T15:25:58","date_gmt":"2025-02-05T16:25:58","guid":{"rendered":"http:\/\/medexperts.pro\/?p=21611"},"modified":"2025-02-05T16:32:20","modified_gmt":"2025-02-05T16:32:20","slug":"novo-nordisk-annual-sales-jump-on-demand-for-ozempic-and-wegovy","status":"publish","type":"post","link":"https:\/\/medexperts.pro\/?p=21611","title":{"rendered":"Novo Nordisk Annual Sales Jump on Demand for Ozempic and Wegovy"},"content":{"rendered":"
<\/div>\n

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.<\/p>\n

\n
\n
\n

Novo Nordisk, the Danish pharmaceutical company behind Ozempic and Wegovy, capped off a somewhat turbulent 2024, reporting profit and revenue on Wednesday that comfortably beat Wall Street expectations. But the drugmaker said it expected sales growth to slow in 2025, as competition increases.<\/p>\n

Novo Nordisk retains its title as Europe\u2019s most valuable company<\/a>, but its share price has dropped about 40 percent since it peaked last June as analysts worried about uncertainty in demand for obesity drugs and the performance of new drugs in trials.<\/p>\n

\u201cLast year was a tale of two halves,\u201d said Emily Field, an analyst at Barclays. The first half of 2024 offered \u201clots of overall excitement.\u201d<\/p>\n

But then data suggested that prescriptions for obesity drugs were growing slowly in the United States, and a few trial results for drugs in the company\u2019s pipeline came in lower than expected, Ms. Field added. President Trump\u2019s election also weighed on pharmaceutical companies in general amid potential changes to health care policy.<\/p>\n<\/div>\n<\/div>\n

<\/div>\n
\n
\n

There\u2019s been \u201ca lot of uncertainty\u201d she said as investors grew more concerned about whether sales of obesity drugs could really meet the industry\u2019s lofty expectations<\/a> of a market larger than $100 billion in the coming decades. Novo Nordisk\u2019s main competitor is the American drugmaker Eli Lilly<\/a>, which also sells obesity drugs.<\/p>\n

On Wednesday, Novo Nordisk said its revenue jumped 25 percent last year<\/a> to 290 billion Danish kroner, or $40.6 billion, driven by growing sales in the United States, and reported profit of more than 100 billion Danish kroner.<\/p>\n

\n
\n
<\/div>\n
\n
\n
\n

We are having trouble retrieving the article content.<\/p>\n

Please enable JavaScript in your browser settings.<\/p>\n<\/div>\n<\/div>\n

\n
\n

Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into<\/a>\u00a0your Times account, or\u00a0subscribe<\/a>\u00a0for all of The Times.<\/p>\n

\n<\/div>\n
\n
\n

Thank you for your patience while we verify access.<\/p>\n

Already a subscriber?\u00a0Log in<\/a>.<\/p>\n

Want all of The Times?\u00a0Subscribe<\/a>.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.Novo Nordisk, the Danish pharmaceutical company behind Ozempic and Wegovy, capped off a somewhat turbulent 2024, reporting profit and revenue on Wednesday that comfortably beat Wall Street expectations. But the drugmaker said it expected sales growth to slow in 2025, as competition increases.Novo Nordisk retains its title as Europe\u2019s most valuable company, but its share price has dropped about 40 percent since it peaked last June as analysts worried about uncertainty in demand for obesity drugs and the performance of new drugs in trials.\u201cLast year was a tale of two halves,\u201d said Emily Field, an analyst at Barclays. The first half of 2024 offered \u201clots of overall excitement.\u201dBut then data suggested that prescriptions for obesity drugs were growing slowly in the United States, and a few trial results for drugs in the company\u2019s pipeline came in lower than expected, Ms. Field added. President Trump\u2019s election also weighed on pharmaceutical companies in general amid potential changes to health care policy.There\u2019s been \u201ca lot of uncertainty\u201d she said as investors grew more concerned about whether sales of obesity drugs could really meet the industry\u2019s lofty expectations of a market larger than $100 billion in the coming decades. Novo Nordisk\u2019s main competitor is the American drugmaker Eli Lilly, which also sells obesity drugs.On Wednesday, Novo Nordisk said its revenue jumped 25 percent last year to 290 billion Danish kroner, or $40.6 billion, driven by growing sales in the United States, and reported profit of more than 100 billion Danish kroner.We are having trouble retrieving the article content.Please enable JavaScript in your browser settings.Thank you for your patience while we verify access. If you are in Reader mode please exit and\u00a0log into\u00a0your Times account, or\u00a0subscribe\u00a0for all of The Times.Thank you for your patience while we verify access.Already a subscriber?\u00a0Log in.Want all of The Times?\u00a0Subscribe.<\/p>\n","protected":false},"author":1,"featured_media":21613,"comment_status":"close","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[],"class_list":["post-21611","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-science"],"_links":{"self":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/21611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21611"}],"version-history":[{"count":2,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/21611\/revisions"}],"predecessor-version":[{"id":21614,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/posts\/21611\/revisions\/21614"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=\/wp\/v2\/media\/21613"}],"wp:attachment":[{"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medexperts.pro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}